INS and metabolic dysfunction-associated steatotic liver disease: Hence, rather than presenting an insulin paradox (Section 2.2), the NAFLD / steatosis aspect of T2D reflects the double-edged activity of mTORC1 in promoting non-glycemic diseases of T2D while interfering with glycemic control.